Compile Data Set for Download or QSAR
Report error Found 170 Enz. Inhib. hit(s) with all data for entry = 10824
TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571658(US11447465, Cmp No. T-168 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571662(US11447465, Cmp No. T-172 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571720(US11447465, Cmp No. T-177)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571646(US11447465, Cmp No. T-156 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571647(US11447465, Cmp No. T-157 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571651(US11447465, Cmp No. T-161 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571649(US11447465, Cmp No. T-159 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571652(US11447465, Cmp No. T-162 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571653(US11447465, Cmp No. T-163 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571552((1R,2S,5S)-3-(2-(3-acetyl- 5-methyl-1H-thieno[3,2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM468665((2S,4R)-1-(2-(3- acetyl-5-(S- methylsulfonimidoyl)...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571551(US11447465, Cmp No. T-1)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571556((1R,3S,5R)-2-(2-(3-acetyl- 6-(S- methylsulfonimido...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571557((1R,2S,5S)-3-(2-(3-acetyl- 6-(S- methylsulfonimido...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571554((2S,4R)-1-(2-(3-acetyl-6- ((E)-S-methyl-N-(2,2,2- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571555((2S,4R)-1-(2-(3-acetyl-6- (S-methylsulfonimidoyl)-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571560((1R,2S,5S)-3-(2-(3-acetyl- 5-methyl-1H-thieno[3,2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571561(US11447465, Cmp No. T-11)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571559((1R,3S,5R)-2-(2-(3-acetyl- 5-(2,2- difluorocyclohe...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571564((2S,4R)-1-(2-(3-acetyl-1H- pyrazol-1-yl)acetyl)-N-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571565(1-(2-((2S,4R)-2-((6- bromopyridin-2- yl)carbamoyl)...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571562((2S,4R)-1-(2-(3-acetyl-5- (5-amino-1,3-dioxan-2-yl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571563((1R,3S,5R)-2-(2-(3-acetyl- 1H-indazol-1-yl)acetyl)...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571582((1R,3S,5R)-2-(2-(3-acetyl- 5-(dimethylamino)-1H- i...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571583((1R,3S,5R)-2-(2-(3-acetyl- 7-methyl-1H-indazol-1- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571588((1R,3S,5R)-2-(2-(3-acetyl- 7-(S-methylsulfinimidoy...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571589((1R,3S,5R)-2-(2-(3-acetyl- 7-(S- methylsulfonimido...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571587((1R,3S,5R)-2-(2-(3-acetyl- 7-methyl-1H-indazol-1- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571592((3-acetyl-1-(2- ((1R,3S,5R)-3-((3-chloro- 2- fluor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571590((1R,3S,5R)-5-(2- azaspiro[3,4]octan-2- ylmethyl)-2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571591((1R,3S,5R)-2-(2-(3-acetyl- 7-methyl-1H-indazol-1- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571597(3-acetyl-1-(2-((1R,3S,5R)- 3-((6-bromo-3- methylpy...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571595((3-acetyl-1-(2- ((1R,3S,5R)-3-((3-chloro- 2- fluor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571569(4-acetyl-1-(2-((2S,4R)-2- ((6-bromopyridin-2- yl)c...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571567(4-acetyl-1-(2-((2S,4R)-2- ((6-bromopyridin-2- yl)c...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571573(3-acetyl-1-(2-((2S,4R)-2- ((6-bromopyridin-2- yl)c...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571571((1R,3S,5R)-2-(2-(3-acetyl- 5-amino-1H-indazol-1- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571577((1R,3S,5R)-2-(2-(3-acetyl- 7-methyl-1H-indazol-1- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571574(3-acetyl-1-(2-((2S,4R)-2- ((6-bromopyridin-2- yl)c...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571575((1R,3S,5R)-2-(2-(3-acetyl- 5-(2,2- difluorocyclope...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571580(3-acetyl-1-(2-((1R,3S,5R)- 3-((6-bromo-3- methylpy...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571581((1R,3S,5R)-2-(2-(3-acetyl- 6-(S- methylsulfonimido...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571578((1R,3S,5R)-2-(2-(3-acetyl- 7-methyl-1H-indazol-1- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571579((1R,3S,5R)-2-(2-(3-acetyl- 5-(3,3-difluoropyrrolid...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571616(US11447465, Cmp No. T-125 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571617(US11447465, Cmp No. T-126 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571614(US11447465, Cmp No. T-123 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571615(US11447465, Cmp No. T-124 | US11447465, Cmp No. T-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM512050(US11084800, Cpd No. 395 | methyl 3-acetyl-1-(2- ((...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM571621(US11447465, Cmp No. T-74)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

Displayed 1 to 50 (of 170 total ) | Next | Last >>
Jump to: